The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial
Study context
- Population
- Critically ill intensive care unit (ICU) patients with sepsis or septic shock and eGFR (Cockcroft-Gault) >60 ml/min, Shiraz, Iran, 2019–2021
- Participants
- 136 patients
- Comparison
- Extended vs intermittent infusion of ampicillin/sulbactam 9 g every 8 h
- Extendedn = 68
- Intermittentn = 68reference
Methodological detailsassessor-blinded, two-centre
- Assessor-blinded
- Two-centre
Further findings
| Outcome | P value |
|---|---|
| Clinical cure | P = 0.039 |
| ICU LOS | P = 0.87 |
| Hospital LOS | 0.83 |
| ICU mortality | P = 0.031 |
| Hospital mortality | P = 0.037 |
Clinical cure
- Significantly higher in the extended group
ICU LOS
- Did not differ between the groups
Hospital LOS
- Did not differ between the groups
ICU mortality
- Significantly lower in the extended infusion group
Hospital mortality
- Significantly lower in the extended infusion group
Original publication
The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial. J Crit Care. Published 19 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →